UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Dual-Action Combination Therapy Enhances Angiogenesis while Reducing Tumor Growth and Spread

Cancer cell, 2015-01, Vol.27 (1), p.123-137

2015

Volltextzugriff (PDF)

Design, synthesis and evaluation of molecularly targeted hypoxia-activated prodrugs

Nature protocols, 2016-04, Vol.11 (4), p.781-794

2016

Volltextzugriff (PDF)

The influence of catechol structure on the suicide-inactivation of tyrosinase

Organic & biomolecular chemistry, 2009-01, Vol.7 (17), p.3388-3390

2009

Volltextzugriff (PDF)

Radiosensitization In Vivo by Histone Deacetylase Inhibition with No Increase in Early Normal Tissue Radiation Toxicity

Molecular cancer therapeutics, 2018-02, Vol.17 (2), p.381-392

2018

Volltextzugriff (PDF)

Phase I Clinical and Pharmacokinetic Evaluation of the Vascular-Disrupting Agent OXi4503 in Patients with Advanced Solid Tumors

Clinical cancer research, 2012-03, Vol.18 (5), p.1415-1425

2012

Volltextzugriff (PDF)

Validation of a method for the determination of the anticancer agent Combretastatin A1 phosphate (CA1P, OXi4503) in human plasma by HPLC with post-column photolysis and fluorescence detection

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2011-09, Vol.879 (25), p.2673-2676

2011

Volltextzugriff (PDF)

Mechanistic studies of the inactivation of tyrosinase by resorcinol

Bioorganic & medicinal chemistry, 2013-03, Vol.21 (5), p.1166-1173

2013

Volltextzugriff (PDF)

Deoxycytidine kinase expression underpins response to gemcitabine in bladder cancer

Clinical cancer research, 2014-11, Vol.20 (21), p.5435-5445

2014

Volltextzugriff (PDF)

The influence of hydroquinone on tyrosinase kinetics

Bioorganic & medicinal chemistry, 2012-07, Vol.20 (14), p.4364-4370

2012

Volltextzugriff (PDF)

Oxidative Metabolism of Combretastatin A-1 Produces Quinone Intermediates with the Potential To Bind to Nucleophiles and To Enhance Oxidative Stress via Free Radicals

Chemical research in toxicology, 2007-12, Vol.20 (12), p.1885-1894

2007

Volltextzugriff (PDF)

Enhanced fluorescence detection of cis-combretastatins by post-column photolysis

Journal of Chromatography A, 2008-02, Vol.1181 (1), p.162-165

Stratford, Michael R.L.

2008

Volltextzugriff (PDF)

A validated HPLC method with fluorescence detection for the glucuronides of Combretastatin A1 in human plasma, and studies on their cis–trans isomerisation

Journal of pharmaceutical and biomedical analysis, 2012-03, Vol.62, p.114-118

2012

Volltextzugriff (PDF)

Hypoxia-driven elimination of thiopurines from their nitrobenzyl prodrugs

Bioorganic & medicinal chemistry letters, 2007-08, Vol.17 (15), p.4320-4322

2007

Volltextzugriff (PDF)

Rapid Halogen Substitution and Dibenzodioxin Formation during Tyrosinase-Catalyzed Oxidation of 4-Halocatechols

Chemical research in toxicology, 2011-03, Vol.24 (3), p.350-356

2011

Volltextzugriff (PDF)

Quantitative determination of the anticancer prodrug combretastatin A1 phosphate (OXi4503, CA1P), the active CA1 and its glucuronide metabolites in human urine and of CA1 in plasma by HPLC with mass spectrometric detection

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2012-06, Vol.898, p.1-6

2012

Volltextzugriff (PDF)

A phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancer

Cancer, 2019-01, Vol.125 (1), p.99-108

2019

Volltextzugriff (PDF)

A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424

British journal of cancer, 2018-03, Vol.118 (6), p.770-776

2018

Volltextzugriff (PDF)

Synthesis and biological properties of bioreductively targeted nitrothienyl prodrugs of combretastatin A-4

Molecular cancer therapeutics, 2006-11, Vol.5 (11), p.2886-2894

2006

Volltextzugriff (PDF)

Oxidative calcium release from catechol

Bioorganic & medicinal chemistry letters, 2015-04, Vol.25 (7), p.1453-1454

2015

Volltextzugriff (PDF)

ZD6126: A novel vascular-targeting agent that causes selective destruction of tumor vasculature

Cancer research (Chicago, Ill.), 2002-12, Vol.62 (24), p.7247-7253

2002

Volltextzugriff (PDF)

Investigation of the anomalous action of 5-hydroxyresorcinol on tyrosinase

Pigment cell and melanoma research, 2016-07, Vol.29 (4), p.474-476

2016

Volltextzugriff (PDF)

Indolequinone Antitumor Agents: Reductive Activation and Elimination from (5-Methoxy-1-methyl-4,7-dioxoindol-3-yl)methyl Derivatives and Hypoxia-Selective Cytotoxicity in Vitro

Journal of medicinal chemistry, 1998-07, Vol.41 (15), p.2720-2731

1998

Volltextzugriff (PDF)

Studies of para-quinomethane formation during the tyrosinase-catalyzed oxidation of 4-alkylcatechols

ARKIVOC, 2008-02, Vol.2008 (2), p.258-267

2008

Volltextzugriff (PDF)

The vascular response of tumor and normal tissues in the rat to the vascular targeting agent, combretastatin A-4-phosphate, at clinically relevant doses

International journal of oncology, 2002-10, Vol.21 (4), p.717

2002

Volltextzugriff (PDF)

Evidence Consistent with the Requirement of Cresolase Activity for Suicide Inactivation of Tyrosinase

The Tohoku Journal of Experimental Medicine, 2008, Vol.216(3), pp.231-238

2008

Volltextzugriff (PDF)

1 – 25 von 95

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(88)
Mit Volltextzugriff
(84)

Publikationsform

Artikel
(95)

Sprache

Englisch
(95)
Japanisch
(21)

Erscheinungsjahr

n.n

Thema

Science & Technology
(80)
Life Sciences & Biomedicine
(68)
Biological And Medical Sciences
(41)
Humans
(39)
Animals
(36)
Medical Sciences
(32)
Chemistry
(28)
Physical Sciences
(27)
Oncology
(25)
Pharmacology. Drug Treatments
(24)
Pharmacology & Pharmacy
(21)
Female
(20)
Male
(20)
Mice
(18)
Chemistry, Medicinal
(17)
Antineoplastic Agents
(16)
Biochemistry & Molecular Biology
(16)
Oxidation-Reduction
(15)
Chemistry, Organic
(13)
Chromatography, High Pressure Liquid
(12)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Dual-Action Combination Therapy Enhances Angiogenesis while Reducing Tumor Growth and Spread

Design, synthesis and evaluation of molecularly targeted hypoxia-activated prodrugs

The influence of catechol structure on the suicide-inactivation of tyrosinase

Radiosensitization In Vivo by Histone Deacetylase Inhibition with No Increase in Early Normal Tissue Radiation Toxicity

Phase I Clinical and Pharmacokinetic Evaluation of the Vascular-Disrupting Agent OXi4503 in Patients with Advanced Solid Tumors

Validation of a method for the determination of the anticancer agent Combretastatin A1 phosphate (CA1P, OXi4503) in human plasma by HPLC with post-column photolysis and fluorescence detection

Mechanistic studies of the inactivation of tyrosinase by resorcinol

Deoxycytidine kinase expression underpins response to gemcitabine in bladder cancer

The influence of hydroquinone on tyrosinase kinetics

Oxidative Metabolism of Combretastatin A-1 Produces Quinone Intermediates with the Potential To Bind to Nucleophiles and To Enhance Oxidative Stress via Free Radicals

Enhanced fluorescence detection of cis-combretastatins by post-column photolysis

A validated HPLC method with fluorescence detection for the glucuronides of Combretastatin A1 in human plasma, and studies on their cis–trans isomerisation

Hypoxia-driven elimination of thiopurines from their nitrobenzyl prodrugs

Rapid Halogen Substitution and Dibenzodioxin Formation during Tyrosinase-Catalyzed Oxidation of 4-Halocatechols

Quantitative determination of the anticancer prodrug combretastatin A1 phosphate (OXi4503, CA1P), the active CA1 and its glucuronide metabolites in human urine and of CA1 in plasma by HPLC with mass spectrometric detection

A phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancer

A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424

Synthesis and biological properties of bioreductively targeted nitrothienyl prodrugs of combretastatin A-4

Oxidative calcium release from catechol

ZD6126: A novel vascular-targeting agent that causes selective destruction of tumor vasculature

Investigation of the anomalous action of 5-hydroxyresorcinol on tyrosinase

Indolequinone Antitumor Agents: Reductive Activation and Elimination from (5-Methoxy-1-methyl-4,7-dioxoindol-3-yl)methyl Derivatives and Hypoxia-Selective Cytotoxicity in Vitro

Studies of para-quinomethane formation during the tyrosinase-catalyzed oxidation of 4-alkylcatechols

The vascular response of tumor and normal tissues in the rat to the vascular targeting agent, combretastatin A-4-phosphate, at clinically relevant doses

Evidence Consistent with the Requirement of Cresolase Activity for Suicide Inactivation of Tyrosinase

Suchergebnisse filtern